Drug Overview:

R-ICE is a multi-drug chemotherapy and targeted therapy regimen used as salvage treatment in relapsed or refractory aggressive B‑cell lymphomas, particularly diffuse large B‑cell lymphoma (DLBCL), and often as a bridge to autologous stem cell transplant. It combines rituximab with the ICE backbone (ifosfamide, carboplatin, etoposide) to enhance the depth of response before high‑dose therapy.

R-ICE is not a single drug but a combination protocol; for clarity, the “generic name” here refers to the regimen and its components.

  • Generic name
    • R-ICE regimen (Rituximab + Ifosfamide + Carboplatin + Etoposide).
  • US Brand names
    • No specific brand name for the regimen; components include:
      • Rituximab (e.g., Rituxan).
      • Ifosfamide (generic).
      • Carboplatin (generic).
      • Etoposide (generic).
  • Drug Class
    • Combined targeted therapy and multi‑agent cytotoxic chemotherapy regimen.
    • Rituximab: CD20‑directed chimeric monoclonal antibody (targeted immunotherapy).
    • Ifosfamide: Alkylating agent (oxazaphosphorine).
    • Carboplatin: Platinum analog (DNA cross‑linking agent).
    • Etoposide: Topoisomerase II inhibitor.
  • Route of Administration
    • All components administered intravenously (IV); rituximab as IV infusion; ifosfamide, carboplatin, etoposide as IV infusions.
  • FDA Approval Status
    • R-ICE as a regimen is standard-of-care salvage therapy but not “FDA‑approved” as a branded combination.
    • Each drug is FDA‑approved for the treatment of lymphoma or related malignancies.
    • Widely endorsed in guidelines (e.g., NCCN) as second‑line/relapsed lymphoma therapy, especially before autologous stem cell transplant.

      R-ice therapy is a powerful treatment for lymphoma. Learn how this effective regimen works to improve patient outcomes and recovery today.

What Is It and How Does It Work? (Mechanism of Action):

R-ICE
R-ICE 2

R-ICE works through complementary mechanisms: antibody‑mediated B‑cell targeting plus multi‑pathway DNA damage and inhibition of DNA repair, leading to apoptosis of malignant B‑lymphocytes.

  • Rituximab – anti‑CD20 targeted immunotherapy
    • Binds CD20, a transmembrane phosphoprotein on normal and malignant B cells, clustering in lipid rafts.
    • Triggers complement‑dependent cytotoxicity (CDC): C1q binding activates complement cascade, forming membrane attack complex and lysing B cells.
    • Induces antibody‑dependent cellular cytotoxicity (ADCC): Fc portion engages Fcγ receptors on NK cells, macrophages, and granulocytes, promoting perforin/granzyme‑mediated killing.
    • Promotes direct apoptosis via signaling pathways (e.g., calcium flux, caspase activation, inhibition of NF‑κB) when cross‑linked.
  • Ifosfamide – DNA alkylation and cross‑linking
    • Pro‑drug activated by hepatic CYP450 to 4‑hydroxyifosfamide, yielding alkylating metabolites (e.g., isophosphoramide mustard).
    • Forms covalent adducts at N7 position of guanine, causing intra‑ and inter‑strand DNA cross‑links.
    • Blocks DNA replication and transcription, triggers DNA damage response, and leads to apoptosis via p53 and intrinsic (mitochondrial) pathways.
    • Co‑administered with mesna to neutralize acrolein and prevent urothelial toxicity.
  • Carboplatin – platinum‑DNA adduct formation
    • Hydrolyzes in plasma to form aquated platinum complexes that bind N7 of guanine and adenine.
    • Creates intra‑ and inter‑strand cross‑links, bending and unwinding DNA, inhibiting DNA synthesis and repair.
    • Synergistic with ifosfamide by overwhelming DNA repair mechanisms and enhancing apoptosis in rapidly dividing lymphoma cells.
  • Etoposide – topoisomerase II inhibition
    • Stabilizes the “cleavable complex” between topoisomerase II and DNA, preventing re-ligation of double-strand breaks.
    • Accumulates DNA breaks during S and G2 phases, causing replication fork collapse and activation of ATM/ATR‑mediated checkpoints.
    • Leads to apoptosis through mitochondrial cytochrome c release and caspase cascade.
  • Combined regimen effect
    • Rituximab selectively targets CD20+ B cells, reducing tumor bulk and sensitizing cells to chemotherapy.
    • Ifosfamide, carboplatin, and etoposide act through distinct DNA‑damaging mechanisms, limiting resistance and providing deep cytoreduction.
    • The multidrug approach enhances complete remission (CR) rates in relapsed/refractory aggressive B‑cell lymphomas compared with ICE alone.

FDA Approved Clinical Indications (List clearly in bullet format)

Because R-ICE is a regimen, indications are protocol‑based rather than labeled as a “single drug,” but its use is well‑standardized in hematologic oncology.

  • Oncological uses
    • Relapsed or refractory diffuse large B‑cell lymphoma (DLBCL) and other aggressive B‑cell non‑Hodgkin lymphomas as second‑line/salvage therapy.
    • Bridge/induction regimen before high‑dose chemotherapy and autologous stem cell transplant in eligible patients.
    • Occasionally used for transformed indolent B‑cell lymphomas (e.g., transformed follicular lymphoma).
  • Non-oncological uses
    • No established non-oncologic indications.
    • Use is confined to malignant hematologic conditions.

Dosage and Administration Protocols:

R-ICE is given in 14‑ or 21‑day cycles, typically 2–4 cycles before stem cell mobilization and transplant evaluation. Dosing is weight/ BSA‑based and adjusted for renal function and marrow reserve.

Component /

Indication		Standard Dose (example adult regimen)Frequency / Cycle LengthInfusion Time / RouteDose Adjustments (renal/hepatic)
Rituximab375 mg/m² IV Day 1Every 14–21 daysFirst infusion 3–6 hours; subsequent 2–4 hoursNo specific renal adjustment; use caution in severe hepatic impairment; premedicate (steroid/antihistamine/antipyretic).
Ifosfamide (with

mesna

uroprotection)		5,000 mg/m² IV (often over 24 hours on Day 2–3)Every 14–21 daysContinuous IV infusion over 20–24 hoursReduce dose in moderate–severe renal impairment; monitor for neurotoxicity (encephalopathy) and adjust or stop if needed.
CarboplatinAUC 5 (approx. 300–500 mg/m²) IV Day 2Every 14–21 days30–60 minute IV infusionDose based on Calvert formula (AUC × [GFR + 25]); adjust for reduced GFR; avoid in severe renal failure or dialyze carefully.
Etoposide100 mg/m² IV Days 1–3Every 14–21 days1–2 hour IV infusion each dayReduce dose in renal impairment and significant hepatic dysfunction; monitor counts closely.


Cycles: Commonly 2–3 cycles before restaging; up to 4–6 cycles if not proceeding to transplant.

  • Growth factor support (e.g., G‑CSF) often used to reduce neutropenia and aid stem cell mobilization.

Clinical Efficacy and Research Results

R-ICE demonstrates strong activity in relapsed/refractory DLBCL, with rituximab addition enhancing ICE backbone efficacy.​

  • Pivotal series: CR rates ~50% (vs 25-30% ICE alone); ORR 60-70% across contemporary cohorts.​
  • PET-CR after 2 cycles predicts superior event-free survival (EFS) and overall survival (OS), enabling 40-60% transplant-eligible patients to proceed.​
  • Real-world data confirm bridge-to-transplant role; 2020-2025 trials (e.g., pembrolizumab + R-ICE) explore deeper responses with immunotherapy combinations.​

Safety Profile and Side Effects

Intensive regimen demands proactive toxicity management.​

Black Box Warning

  • Rituximab: Fatal infusion reactions (first dose), HBV reactivation/failure, PML.​
  • Components: Severe myelosuppression, secondary malignancies, organ toxicities.​

Common side effects (>10%)

  • Neutropenia (grade 3-4 ~70%), anemia/thrombocytopenia, nausea/vomiting, fatigue, alopecia, rituximab chills/fever.
  • Management: G-CSF day +7, antiemetics (5HT3 + NK1/aprepitant), transfusions PRN, rituximab premeds (acetaminophen/diphenhydramine ± steroid), slow infusion ramp-up.​

Serious adverse events

  • Febrile neutropenia/sepsis, hemorrhagic cystitis, ifosfamide encephalopathy, carboplatin hypersensitivity/nephrotoxicity, etoposide myelosuppression.
  • Management: Broad-spectrum Abx + G-CSF for FN; mesna + 3L/m² hydration for cystitis; methylene blue/thiamine for encephalopathy; HBV screen/prophylaxis (entecavir); desensitization or switch for platinum allergy.​

Connection to Stem Cell and Regenerative Medicine (If Applicable)

Designed as a transplant bridge; facilitates stem cell mobilization.​

  • Achieves cytoreduction + G-CSF synergy for CD34+ collection; CR/PR patients advance to HDT/ASCT with ~50% long-term remission rates.
  • Emerging: Immunotherapy augmentation (PD-1 inhibitors) targets MRD pre-transplant.​

Patient Management and Practical Recommendations

Requires hematology/transplant team coordination.​

  • Pre-treatment tests: H&P/ECOG, CBC/chemistries, HBV/HCV/HIV serologies, echo/EF if prior anthracycline, audiology/renal baseline, PET-CT disease burden.​
  • Precautions: qWeek CBCs cycle 1, neuro checks during ifosfamide, infusion monitoring, infection prophylaxis (levofloxacin/acylovir).​
  • Do’s
    • Teach fever/neutropenia signs; daily mouth care.
    • G-CSF + antifungals per risk.
    • Early ASCT referral for responders.​
  • Don’ts
    • Omit HBV screen/antivirals.
    • Ignore confusion/hallucinations (ifosfamide hold).
    • Dose without count recovery.​

Legal Disclaimer:

This content is for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. Treatment decisions for R-ICE and related therapies must be made by qualified healthcare professionals based on individual patient factors, current clinical guidelines, and official prescribing information.